Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #57 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| IOL Chemicals and Pharmaceuticals Limited (this stock) | 6,038 | 35.9 | 7.7% | 98.0% | — | 71 | 26 | 53 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 756 | 87 | 64 | ₹ |
| March 31, 2026 | 619 | 71 | 53 | ₹ |
| Dec. 31, 2025 | 580 | 28 | 21 | ₹ |
| Sept. 30, 2025 | 568 | 40 | 30 | ₹ |
| June 30, 2025 | 552 | 46 | 34 | ₹ |
| March 31, 2025 | 528 | 45 | 31 | ₹ |
| Dec. 31, 2024 | 523 | 28 | 21 | ₹ |
| Sept. 30, 2024 | 526 | 26 | 19 | ₹ |
| June 30, 2024 | 502 | 40 | 30 | ₹ |
| March 31, 2024 | 504 | 37 | 28 | ₹ |
| Dec. 31, 2023 | 520 | 32 | 23 | ₹ |
| Sept. 30, 2023 | 545 | 51 | 38 | ₹ |
| June 30, 2023 | 563 | 61 | 46 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,319 | 184 | 138 |
| March 31, 2025 | 2,079 | 138 | 101 |
| March 31, 2024 | 2,133 | 182 | 134 |
| March 31, 2023 | 2,217 | 189 | 139 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 214 | -198 | -29 | 173 | 41 |
| March 31, 2025 | 179 | -154 | 46 | 214 | -35 |
| March 31, 2024 | 290 | -191 | -92 | 274 | 16 |
| March 31, 2023 | 122 | -120 | -4 | 212 | -90 |
| March 31, 2022 | 93 | -120 | -2 | 153 | -60 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 2,587 | 1,799 | 1,740 | 132 | 0 | 1,228 | 690 | 65 | 1,165 | 371 |
| March 31, 2025 | 2,382 | 1,688 | 1,629 | 117 | 0 | 1,151 | 610 | 78 | 1,158 | 361 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
